Bank of America’s Ventyx Biosciences VTYX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-316,856
Closed -$2.86M 6901
2025
Q4
$2.86M Sell
316,856
-212,393
-40% -$1.59M ﹤0.01% 3789
2025
Q3
$1.65M Sell
529,249
-309,138
-37% -$819K ﹤0.01% 4977
2025
Q2
$1.79M Sell
838,387
-178,262
-18% -$288K ﹤0.01% 4870
2025
Q1
$1.17M Sell
1,016,649
-3,256,793
-76% -$5.59M ﹤0.01% 5115
2024
Q4
$9.36M Buy
4,273,442
+3,376,446
+376% +$7.65M ﹤0.01% 3015
2024
Q3
$1.96M Buy
896,996
+483,862
+117% +$1.11M ﹤0.01% 4579
2024
Q2
$954K Buy
413,134
+109,894
+36% +$457K ﹤0.01% 4932
2024
Q1
$1.67M Buy
303,240
+251,356
+484% +$1.15M ﹤0.01% 4568
2023
Q4
$128K Buy
51,884
+3,912
+8% +$37.2K ﹤0.01% 6277
2023
Q3
$1.67M Sell
47,972
-22,215
-32% -$768K ﹤0.01% 4432
2023
Q2
$2.3M Sell
70,187
-7,491
-10% -$258K ﹤0.01% 4105
2023
Q1
$2.6M Buy
77,678
+23,948
+45% +$931K ﹤0.01% 4109
2022
Q4
$1.76M Buy
53,730
+42,965
+399% +$1.27M ﹤0.01% 4366
2022
Q3
$375K Sell
10,765
-5,198
-33% -$115K ﹤0.01% 5599
2022
Q2
$195K Sell
15,963
-14,717
-48% -$220K ﹤0.01% 6119
2022
Q1
$416K Sell
30,680
-16,247
-35% -$217K ﹤0.01% 5961
2021
Q4
$932K Buy
+46,927
New +$889K ﹤0.01% 5357

Other funds holding VTYX

Bank of America's VTYX Position: Q1 2026 in Review

Bank of America sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 316,856 shares — an estimated $2.86M sold.

Bank of America first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $9.36M in Q4 2024. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.

  • Bank of America reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 316,856 Ventyx Biosciences shares in Q1 2026, an estimated $2.86M.
  • Bank of America first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
  • Bank of America's Ventyx Biosciences position peaked at $9.36M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.